Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family by Hideaki Hasegawa et al.
November 2016 | Volume 7 | Article 4791
Review
published: 04 November 2016
doi: 10.3389/fimmu.2016.00479
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Masaaki Murakami, 
Hokkaido University, Japan
Reviewed by: 
Daisuke Kamimura, 
Hokkaido University, Japan  
Akihiro Kimura, 
National Center for 
Global Health and 
Medicine, Japan
*Correspondence:
Takayuki Yoshimoto  
yoshimot@tokyo-med.ac.jp
Specialty section: 
This article was submitted 
to Inflammation, 
a section of the journal 
Frontiers in Immunology
Received: 30 July 2016
Accepted: 20 October 2016
Published: 04 November 2016
Citation: 
Hasegawa H, Mizoguchi I, Chiba Y, 
Ohashi M, Xu M and Yoshimoto T 
(2016) Expanding Diversity 
in Molecular Structures and 
Functions of the IL-6/IL-12 
Heterodimeric Cytokine Family. 
Front. Immunol. 7:479. 
doi: 10.3389/fimmu.2016.00479
expanding Diversity in 
Molecular Structures and 
Functions of the iL-6/iL-12 
Heterodimeric Cytokine Family
Hideaki Hasegawa, Izuru Mizoguchi, Yukino Chiba, Mio Ohashi, Mingli Xu  
and Takayuki Yoshimoto*
Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
The interleukin (IL)-6/IL-12 family cytokines have pleiotropic functions and play critical 
roles in multiple immune responses. This cytokine family has very unique characteristics 
in that they comprise two distinct subunits forming a heterodimer and each cytokine 
and receptor subunit shares with each other. The members of this cytokine family are 
increasing; currently, there are more than six cytokines, including the tentatively named 
cytokines IL-Y (p28/p40), IL-12 (p35/p40), IL-23 (p19/p40), IL-27 [p28/Epstein–Barr 
virus-induced protein 3 (EBI3)], IL-35 (p35/EBI3), and IL-39 (p19/EBI3). This family of 
cytokines covers a very broad range of immune responses, including pro-inflammatory 
responses, such as helper T (Th)1, Th2, and Th17, to anti-inflammatory responses, such 
as regulatory T (Treg) cells and IL-10-producing Treg cells. IL-12 is the first member 
of this family, and IL-12, IL-23, and IL-27 are mainly produced by activated antigen-
presenting cells, such as dendritic cells and macrophages. IL-12 plays a critical role in 
the promotion of Th1 immune responses by inducing interferon-γ production to combat 
pathogens and malignant tumors. IL-23 induces IL-17 production and is necessary to 
maintain pathogenic Th17 cells that cause inflammatory and autoimmune diseases. 
IL-27 was initially reported to play a critical role in promotion of Th1 differentiation; 
however, subsequent studies revealed that IL-27 has broader stimulatory and inhibitory 
roles by inducing IL-10-producing Treg cells. IL-35 is produced by forkhead box P3+ 
Treg cells and activated B cells and has immunosuppressive functions to maintain 
immune tolerance. The most recently identified cytokine, IL-39, is produced by activated 
B cells and has pro-inflammatory functions. The cytokine tentatively named IL-Y seems 
to have anti-inflammatory functions by inhibiting Th1 and Th17 differentiation. In addition, 
individual cytokine subunits were also shown to have self-standing activities. Thus, 
promiscuity within the IL-6/IL-12 family cytokines complicates structural and functional 
clarification and assignment of individual cytokines. A better understanding of the recent 
advances and expanding diversity in molecular structures and functions of the IL-6/IL-12 
family cytokines could allow the creation of novel therapeutic strategies by using them as 
tools and targeted molecules.
Keywords: iL-6, iL-12, iL-23, iL-27, iL-30, iL-35, iL-39, iL-Y
Abbreviations: CLF, cytokine-like factor 1; EBI3, Epstein–Barr virus-induced protein 3; gp130, glycoprotein 130; IFN, inter-
feron; Ig, immunoglobulin; IL, interleukin; NK, natural killer; R, receptor; s, soluble; STAT, signal transducer and activator of 
transcription; Th, helper T; Treg, regulatory T.
FiguRe 1 | The iL-6/iL-12 family cytokines. The IL-6/IL-12 family cytokines have pleiotropic functions and play critical roles in multiple immune responses. 
This cytokine family has very unique characteristics, because they are composed of two distinct subunits forming a heterodimer and each cytokine and receptor 
subunit shares with each other. The members of this cytokine family are increasing. Currently, there are more than six cytokines, including tentatively named 
cytokines.
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iNTRODuCTiON
Generally, cytokines are grouped into distinct families depending 
on the differences in homology among amino acid sequences 
and structural characteristics. These characteristics include the 
protein higher-order structure and usage of certain membrane-
bound cytokine β-receptors for signal transduction. In particular, 
the interleukin (IL)-6/IL-12 family cytokines have unique 
structure properties in that they comprise distinct α-subunits 
and β-subunits forming a heterodimer and they share cytokine 
subunits and cellular receptors with each other (1–3). The 
α-subunit is a four-helix bundle, long-chain structure similar 
to the type I cytokine, IL-6, and includes IL-23/IL-39p19, IL-27/
IL-30p28, and IL-12/IL-35p35. The β-subunit is composed of 
two tandem fibronectin type III domains that form a cytokine-
binding homology region and an N-terminal immunoglobulin 
(Ig) domain. This subunit is structurally related to the non-
signaling receptor of IL-6, soluble IL-6 α-receptor (sIL-6Rα), and 
includes IL-12/IL-23p40 and IL-27/IL-35/IL-39 Epstein–Barr 
virus-induced protein 3 (EBI3). By promiscuous pairing between 
these α-subunits and β-subunits, more than six heterodimeric 
cytokines were reported to exist (Figure 1).
Interleukin-6 is one of the most important inflammatory 
cytokines; it is unique in signaling through not only membrane-
bound IL-6Rα but also sIL-6Rα together with ubiquitously 
expressed β-receptor glycoprotein 130 (gp130) (4, 5). The former 
is called IL-6 classic signaling through membrane-bound IL-6Rα 
together with gp130 (4, 5). In contrast, the latter is called IL-6 
trans-signaling by IL-6 bound with sIL-6Rα and IL-6/sIL-
6Rα (also designated Hyper-IL-6), which is generated under 
pathological conditions, and signals only through gp130 as a 
receptor (4, 5). Because the IL-6/sIL-6Rα complex is similar in 
molecular structure to the IL-12 family heterodimeric cytokines 
and has homology with the IL-12 family cytokines, IL-6 and the 
IL-12 family cytokines are generally called IL-6/IL-12 family 
cytokines. This family of cytokines has emerged as key players 
in promotion and suppression of multiple immune responses 
under physiological and pathological situations.
FiguRe 2 | Recent advances in molecular structures and functions of the iL-6/iL-12 family cytokines. Promiscuity within the IL-6/IL-12 family cytokines 
complicates the structural and functional clarification and assignment of individual cytokines. The roles of this family of cytokines are expanding, and individual 
cytokine subunits have been shown to have self-standing activities. This illustrates the recent advances in molecular structures and functions of the IL-6/IL-12 family 
cytokines. Up-arrow in blue and down-arrow in red mean upregulation and downregulation of expression, respectively. Breg, regulatory B; CCl4, carbon 
tetrachloride; CLF, cytokine-like factor 1; Con A, concanavalin A; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; EAU, experimental 
autoimmune uveitis; HSC, hematopoietic stem cell; ICAM-1, intracellular adhesion molecule-1; LPS, lipopolysaccharide; MΦ, macrophage; NOD, non-obese 
diabetic; TLR, toll-like receptor; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule-1.
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Interleukin-12 is the first member of this family and 
consists of two subunits, p35 connected to an intra-chain 
disulfide with soluble α-receptor p40 (6, 7). p40 also binds 
to another β-subunit, p19, by the disulfide bridge to form the 
second heterodimeric cytokine called IL-23 (8), whereas p40 
alone forms the antagonistic or agonistic disulfide-connected 
homodimer p80 (9). IL-12 and IL-23 engage a heterodimeric 
receptor complex of IL-12Rβ1 and IL-12Rβ2 and of IL-12Rβ1 
and IL-23R, respectively, and share IL-12Rβ1 for signaling 
(10). IL-27 consists of two subunits, p28 (IL-30) and a soluble 
α-receptor EBI3, and signals via a receptor complex of WSX-1 
and gp130 (11). IL-27 differs from the other IL-6/IL-12 family 
cytokines in that its subunits are not covalently linked. IL-35 
shares the EBI3 of IL-27 and signals via four different receptor 
complexes: IL-12Rβ2/gp130, IL-12Rβ2/IL-12Rβ2, gp130/gp130, 
and IL-12Rβ2/WSX-1 (12, 13). IL-39, which was most recently 
discovered, consists of EBI3 and p19 and signals via IL-12Rβ1 
and IL-23R (14). p40 also binds to p28 to form p28/p40, ten-
tatively called IL-Y, but this complex was demonstrated to be 
an antagonist to the signaling by IL-12 and IL-27 (15, 16). In 
addition, biological activities of monomeric forms of p28 (17), 
EBI3 (18), and p19 (19) and generation of soluble receptors of 
WSX-1 (20) and IL-23R (21) as antagonists to IL-27 and IL-23, 
respectively, were reported as well.
In this review, we summarize and discuss the recent advances 
and expanding diversity in molecular structures and functions 
of the IL-6/IL-12 family cytokines (Figure 2) to enable a better 
understanding of them and their use as tools and targeted mol-
ecules for novel therapeutic strategies.
iNTeRLeuKiN-27
Interleukin-27 is a multifunctional cytokine with both pro-
inflammatory and anti-inflammatory properties (11, 22). 
Although initial studies demonstrated the critical role of IL-27 
in the induction of helper T (Th)1 differentiation (23–27), sub-
sequent studies revealed that IL-27 has broader stimulatory and 
inhibitory roles in T-cell proliferation, differentiation, cytokine 
production, and effector functions (11, 22). IL-27 prevents the 
development of autoimmune diseases, such as experimental 
autoimmune encephalomyelitis and arthritis, by inhibiting Th17 
differentiation and immune responses (28). In addition, IL-27 not 
only promotes protective Th1 immune responses against patho-
gens but also suppresses them, limiting excessive inflammation 
FiguRe 3 | iL-35 and the composition of its receptor subunits. IL-35, a 
heterodimeric cytokine of p35 and EBI3, is preferentially secreted by forkhead 
box P3 (Foxp3+) Treg cells and induces IL-35-producing Treg (iTR35) cells 
with immunosuppressive activity. The receptor for IL-35 is a heterodimer of 
gp130 and IL-12Rβ2, and it signals via activation of a heterodimer of STAT1 
and STAT4. In addition, IL-35 also has the ability to mediate signaling in the 
presence of only one of them as a homodimer. IL-35 also produced from 
CD19+CD138hi B cells induces the expansion of B regulatory (Breg) cells 
producing IL-35 and, intriguingly, activates a heterodimer of STAT1 and 
STAT3 through the IL-35 receptor comprising IL-12Rβ2 and WSX-1.
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(29, 30) in part by IL-27-mediated induction of IL-10-producing 
regulatory T (Treg) cells (31, 32).
Host control of infections mainly induces Th1 responses in 
which interferon (IFN)-γ, IL-12, and tumor necrosis factor-α play 
critical roles in eliciting protective immunity against parasites, 
such as Toxoplasma and Plasmodium. However, continuing 
activation of effector immune cells provokes overproduction of 
pro-inflammatory cytokines, leading to exacerbated inflamma-
tory reaction and lethality. Anti-inflammatory cytokines, such as 
IL-10 and IL-27, were demonstrated to be important for limiting 
the exacerbated protective Th1 responses (33–36). Moreover, 
malaria infection inhibits immune responses to the parasite itself, 
and CD4+ T cells from malaria-infected mice and humans have 
defects in the ability to produce IL-2 in response to T-cell receptor 
stimulation (37). Recently, a unique subpopulation of malaria-
specific CD4+ T cells was revealed to produce IL-27 in response 
to T-cell receptor stimulation, subsequently inhibiting IL-2 
production and clonal expansion of other T cells (38). The IL-27-
producing CD4+ T cells are forkhead box P3− CD11a+CD49d+ 
malaria antigen-specific CD4+ T cells, and they are distinct 
from IFN-γ-producing Th1 or IL-10-producing Treg cells (38). 
Thus, IL-27-producing regulatory CD4+ T cells, designated Tr27 
cells, play a critical role in the regulation of protective immune 
responses against malaria parasites.
During infection, cytokines play pivotal roles in both induc-
tion of protective immunity and exacerbation of inflammatory 
responses. Multiple mechanisms to induce protection of the host 
from infection have been reported. Emergency myelopoiesis, 
which is one of these protective responses, is inflammation-
induced hematopoiesis to replenish myeloid cells in the periph-
ery, which is critical for controlling infection with pathogens 
(39, 40). Transgenic mice expressing IL-27 previously showed 
enhanced myelopoiesis in the bone marrow and extramedul-
lary hematopoiesis in the spleen (41). Hematopoietic stem cells 
express both IL-27R subunits, such as WSX-1 and gp130 (41). 
IL-27 was recently revealed to directly act on hematopoietic 
stem cells and promote their expansion and differentiation to 
myeloid progenitor cells in  vitro and in  vivo in synergy with 
stem cell factor (42). In addition, it was demonstrated that 
IL-27 plays an important role in the control of infection with 
Plasmodium berghei-attenuated variant XAT. IL-27, which is 
produced through IFN-γ production during malaria infection, 
promotes expansion and differentiation of hematopoietic stem 
cells to myeloid progenitors and mobilizes them into the spleen, 
resulting in enhanced myelopoiesis with increased numbers of 
mature myeloid cells such as neutrophils (42). Thus, IL-27 is one 
of the limited unique cytokines directly acting on hematopoietic 
stem cells and promoting their expansion and differentiation 
into myeloid progenitor cells.
Accumulating evidence revealed the potent antitumor 
activi ties of IL-27 through multiple mechanisms, including 
CD8+ T  cells, natural killer (NK) cells, antibody-dependent 
 cell-mediated cytotoxicity, anti-angiogenesis, direct anti- 
proliferative effect, inhibition of expression of cyclooxygenase-2 
and prostaglandin E2, and suppression of epithelial–mesenchymal 
transition, depending on the characteristics of individual tumors 
(43–45). One of the most critical tumor suppressors, p53, is 
inherently instable and mutated in approximately 50% of tumors, 
and various stressors such as DNA damage or oncogenic activa-
tion such as RAS mutations can affect the oncogenic properties of 
the mutant p53 (46). Because IL-27 possesses anti-inflammatory 
and antitumor properties, the role of endogenous IL-27 signaling 
in the mutant p53-mediated tumorigenesis was investigated (47). 
Lack of IL-27 signaling was shown to decrease the survival and 
double the incidence of osteosarcoma, possibly due to increased 
stability of the mutant p53 protein expression, indicating that 
IL-27 signaling negatively modulates the oncogenic properties of 
mutant p53 in vivo (47). In addition, lack of IL-27 signaling was 
demonstrated to cause spontaneous liver inflammation, fibrosis, 
and steatosis (48).
iNTeRLeuKiN-35
Interleukin-35 is preferentially secreted by forkhead box P3+ 
Tregs and has suppressive activity (12). IL-35 also induces the 
conversion of conventional T cells into a suppressive IL-35-
producing forkhead box P3−-induced Treg-cell population 
(termed iTr35), and this contagious spread of suppression is 
known as infectious tolerance (49). The receptor for IL-35 is 
a heterodimer of gp130 and IL-12Rβ2. In addition, IL-35 has 
the ability to mediate signaling in the presence of only one of 
them as a homodimer through activation of the heterodimer 
or homodimer of signal transducer and activator of transcrip-
tion (STAT)1 and STAT4 (13) (Figure 3). In B cells, IL-35 was 
recently demonstrated to induce the expansion of a unique 
IL-35-producing regulatory B cell that conferred protection 
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from experimental autoimmune uveitis (50). Intriguingly, 
IL-35 activates a heterodimer of STAT1 and STAT3 through 
the IL-35 receptor comprising the IL-12Rβ2 and WSX-1 in B 
cells (50). Moreover, B cell-restricted deficiency in p35 or EBI3 
exacerbated experimental autoimmune encephalomyelitis and 
enhanced resistance to Salmonella infection (51).
The testis has immune privilege, and the maintenance of that 
immune privilege status in the testes is controlled by multiple 
mechanisms, including the sequestration of antigens and anti-
bodies from the immune system by the blood–testis barrier, the 
immunosuppressive properties of local cells, and the production 
of paracrine and endocrine factors (52, 53). Expression of EBI3 
was recently demonstrated to markedly increase in the testes of 
10- or 12-week-old wild-type mice as compared with levels in 
2-week-old mice, whereas mRNA expression of p35 was con-
served between these two groups (54). Lack of EBI3, p35, and 
IL-12Rβ2 caused enhanced infiltration of lymphocytes into the 
testicular interstitium with increased IFN-γ expression in the 
testes and autoantibody production against mainly acrosomal 
regions of spermatids (54). Immunohistochemical analyses 
revealed that CD163+ resident macrophages positive for p35 and 
EBI3, possibly producing IL-35, were detected in the interstitium 
of 12-week-old mice, but not in those of 2-week-old mice (54). 
These results suggest that IL-35 contributes to maintaining the 
testicular immune privilege.
It was previously demonstrated that there are multiple IL-35+ 
cells in tumor-bearing mice and patient samples and that forced 
expression of IL-35 in a tumor promotes tumor progression (49, 
55). Recently, the physiological impact of IL-35 on the tumor 
microenvironment was examined (56). Neutralization with 
IL-35-specific antibody or Treg cell-restricted deletion of IL-35 
production limited tumor growth in multiple tumor models 
due to enhanced T-cell proliferation, effector function, antigen-
specific responses, and long-term T-cell memory (56). Thus, 
IL-35 plays critical roles in preventing autoimmunity, maintain-
ing self-tolerance, and suppressing antitumor immune responses.
iNTeRLeuKiN-39
Interleukin-39 is the most recently discovered cytokine. It 
belongs to the IL-6/IL-12 family and consists of IL-12/IL-23p19 
and IL-27/IL-35EBI3, whose stable association was demonstrated 
in culture supernatant of activated B cells by immunoprecipita-
tion (14). Secretion of IL-39 by activated B cells that mediate 
lupus-like diseases in MRL/lpr mice was demonstrated to be 
significantly elevated compared to other IL-12 family cytokines. 
In addition, adoptive transfer of activated B cells depleted of p19 
or EBI3 to mice with lupus-like disease ameliorated hallmark 
features of systemic lupus erythematosus, including reduction 
of splenomegaly, pathogenic B cells, and proteinuria (14). IL-39 
was also shown to induce differentiation and/or expansion of 
neutrophils, whose ability is critically important for induction of 
pathogenic features of the autoimmune disease (57). Moreover, 
IL-39-induced neutrophils had positive feedback on IL-39 expres-
sion in activated B cells by secreting B-cell activation factor (57). 
Thus, IL-39 secreted by activated B cells may be an important 
pro-inflammatory cytokine and a potential therapeutic target 
for the treatment of autoimmune diseases such as systemic lupus 
erythematosus.
A similar possible association between p19 and EBI3 was 
suggested in damaged keratinocytes (58). In keratinocytes, 
toll-like receptor 3 has an important role in detecting damage-
associated molecular patterns released from damaged cells 
and in initiating cell repair processes (59). Toll-like receptor 
3-mediated activation of keratinocytes was demonstrated 
to drive IFN regulatory factor 6-dependent p19 expression 
and p19/EBI3 heterodimer formation, possibly contributing 
to wound healing by damping inflammatory responses (58). 
Further studies are necessary to clarify whether IL-39 is a 
pro-inflammatory cytokine or an anti-inflammatory cytokine, 
or both, in keratinocytes.
iL-Y (p28/p40)
The α-subunit of IL-27, p28, which is referred to as IL-30, was 
initially reported to inhibit gp130 signaling by directly binding 
to gp130, resulting in inhibition of Th17 differentiation as an 
antagonist (60). However, IL-30 was demonstrated to function 
as an agonistic cytokine via the gp130 signaling pathway similar 
to IL-6, either by itself or associated with other molecules, such 
as IL-12p40 (15, 16), cytokine-like factor 1 (CLF) (61), IL-6Rα 
(62), forming p28/IL-6Rα classic signaling, p28/sIL-6Rα trans-
signaling, and p28 signaling (Figure 4).
After identification of IL-35 in 2007 (12), additional poten-
tial pairings were examined; one of these candidates was the 
IL-27p28/IL-12p40 heterodimer (15). Initial studies using 
Western blot followed by immunoprecipitation reaction revealed 
that a stable association between p28 and p40 was formed 
possibly via disulfide bond (15). The therapeutic effect of p28/
p40 was then examined using a mouse model of experimental 
autoimmune uveitis, which is caused by Th1 and Th17 cells. 
Injection of p28/p40 protein suppressed experimental autoim-
mune uveitis by inhibiting the differentiation and inflammatory 
responses of Th1 and Th17 cells (15). These suppressive effects 
seemed to be ascribed to antagonizing the activation of STAT1 
and STAT3 pathways induced by IL-27 and IL-6, both of which 
signal through the gp130 receptor (15). Moreover, recent studies 
using adenovirus vector expressing p28/p40 (IL-Y) suggested 
that treatment of prediabetic non-obese diabetic mice prevented 
the onset of hyperglycemia with reduced expression of inflam-
matory mediators such as IFN-γ (16). Interestingly, in this study, 
p28/p40 was demonstrated to be able to significantly stimulate 
a unique cytokine and chemokine expression profile as well as 
to activate STAT3, in part, through a pathway involving WSX-1 
(16). These results implicate that the p28/p40 might be a bioac-
tive immunosuppressive cytokine and not a mere competitive 
inhibitor against IL-27, IL-12, or IL-23.
p28/CLF
Independently of EBI3, p28 also forms a complex with CLF, 
and the resultant p28/CLF complex is produced by activated 
dendritic cells (61). CLF is a soluble cytokine receptor that 
forms a complex with cardiotrophin-like cytokines, which have 
FiguRe 4 | iL-30 and its related molecules. IL-6 is unique in signaling 
through not only membrane-bound IL-6Rα but also sIL-6Rα. The former is 
called IL-6 classic signaling through membrane-bound IL-6Rα together with 
gp130, and the latter is called IL-6 trans-signaling by IL-6 bound with 
sIL-6Rα and IL-6/sIL-6Rα (also designated Hyper-IL-6) through only gp130. 
The α subunit of IL-27, p28, which is referred to as IL-30, functions as an 
agonistic cytokine via the gp130 signaling pathway similar to IL-6, either by 
itself or associating with other molecules such as IL-12p40, CLF, IL-6Rα, 
forming p28/IL-6Rα classic signaling, p28/sIL-6Rα trans-signaling, and p28 
signaling. Moreover, p28 can activate signal transduction via gp130, even in 
the absence of IL-6Rα or EBI3, albeit at higher concentrations.
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neurotrophic and immunomodulatory activities, for efficient 
secretion (63). p28/CLF was demonstrated to activate NK cells 
with IL-12-induced and IL-2-induced IFN-γ production and to 
induce activation of STAT1 and STAT3, which requires gp130 
and IL-6Rα, but not WSX-1, as receptor subunits for signaling in 
CD4+ and CD8+ T cells (61). It also promoted IL-17 and IL-10 
secretion from CD4+ T cells and inhibited their proliferation. 
In B cells, p28/CLF enhanced their proliferation and induced 
differentiation into plasma cells producing IgM, IgG2c, and IgG1 
(64). In the factor-dependent B-cell line, Ba/F3 cells expressing 
gp130 and IL-6Rα, p28/CLF induced activation of STAT1 and 
STAT3 and their proliferation (61). Similar effects were also 
observed with p28 alone, indicating that p28 alone is biologically 
active in cells expressing gp130 and IL-6Rα, such as hepatocytes 
like IL-6 (61, 62). This is because CLF is assumed to be neces-
sary only for secretion of p28, but not for p28/IL-6Rα-mediated 
signaling (61, 62).
p28/siL-6Rα (p28 TRANS-SigNALiNg)
Because IL-6Rα is only expressed in hepatocytes and subtypes 
of lymphocytes, but gp130 is almost ubiquitously expressed, 
IL-6 can signal via not only the membrane-bound IL-6Rα and 
gp130 (IL-6 classic signaling) but also the sIL-6Rα through 
only gp130 (IL-6 trans-signaling); serum levels of sIL-6Rα are 
increased under inflammatory conditions and the spectrum of 
IL-6-responsive cells expands to almost all types of cells through-
out the body (2, 5). Similarly, p28 can also induce signaling via 
membrane-bound IL-6Rα; therefore, p28 was speculated to 
induce trans-signaling via sIL-6Rα (61). Indeed, p28/sIL-6Rα 
fusion protein similar to IL-6/sIL-6Rα (Hyper-IL-6) was shown 
to induce phosphorylation of STAT3 and proliferation of Ba/F3 
cells expressing gp130, which are inhibited by soluble gp130 (62). 
Although the findings of p28/sIL-6Rα trans-signaling expand 
the spectrum of its responsive cells to virtually all cells in the 
body, such as IL-6, physiological roles of the p28/sIL-6Rα trans-
signaling remain to be clarified.
iL-30 (p28) (p28 CLASSiC SigNALiNg)
Although IL-27 signals via a heterodimer of gp130 and WSX-1, 
p28/IL-6Rα was demonstrated to specifically recruit two gp130 
receptors for signal transduction (62). The binding of p28 to a 
gp130/WSX-1 heterodimer or a gp130 homodimer was revealed 
to be highly selective and controlled by a novel molecular switch 
induced by EBI3 (as IL-27) or IL-6Rα (as p28 classic signaling), 
respectively (62). Moreover, because p28 has an intrinsic affinity 
for gp130 (60), p28 was able to activate signal transduction via 
gp130, even in the absence of IL-6Rα or EBI3, albeit at higher 
concentrations (62).
Recent evidence suggested that IL-30 also acts as an IL-27-
independent self-standing cytokine with its own functions in 
addition to associating with EBI3 to form IL-27. These functions 
include a hepatoprotective role against liver injury and liver 
fibrosis induced by acute and chronic inflammation with IL-12, 
IFN-γ, concanavalin A, and carbon tetrachloride (65–67). This 
is consistent with the fact that IL-6Rα is mainly expressed on 
hepatocytes (4, 5, 62). Injection of the IL-30 expression vector 
was demonstrated to inhibit IL-12-induced and concanavalin 
A-induced liver injury due to suppression of IFN-γ production 
(65). Consistent with this, dendritic cell-specific p28 conditional 
knockout mice exacerbated concanavalin A-induced liver injury 
with higher production of IFN-γ from CD4+ T cells, but not NKT 
cells (66). In addition, injection of the IL-30 expression vector 
attenuated liver fibrosis by recruiting NKT cells into the liver to 
remove activated hepatic stellate cells through an NKG2D–Rae1 
interaction (67).
Moreover, IL-30, but not EBI3, was demonstrated to be 
expressed in prostate cancer lesions and tumor-draining lymph 
nodes, such as CD68+ macrophages, CD33+/CD11b+ myeloid 
cells, and CD14 monocytes, and its expression correlated with 
advanced disease grade and stage (68). In addition, IL-30 stimu-
lated proliferation of human prostate cancer cells, which express 
both IL-6Rα and gp130, and downregulated the expression of 
chemokines, such as CCL16, tumor necrosis factor superfamily 
member 14, and chemokine-like factor, which recruit immune 
cells into the tumor (68). IL-30 also upregulated the tumor sup-
pressor and androgen co-receptor CKLF-like MARVEL trans-
membrane domain containing-3 and multifunctional receptor 
chemokine-like receptor-1 (68). Thus, IL-30 may be an important 
cytokine shaping the tumor and lymph node microenvironment.
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ePSTeiN–BARR viRuS-iNDuCeD 
PROTeiN 3
Epstein–Barr virus-induced protein 3 was first identified in B 
lymphocytes as a gene whose expression is induced by Epstein–
Barr virus infection and is readily secreted by itself (69). Recently, 
evidence revealed that EBI3 may also function as a self-standing 
molecule. It was demonstrated that high expression of EBI3 in 
lung cancer patients is associated with a poor prognosis and that 
serum levels of EBI3 in lung cancer patients are significantly higher 
than those in healthy volunteers (70). Furthermore, reduction of 
EBI3 expression by siRNA suppressed cancer cell proliferation 
and induction of exogenous EBI3 expression conferred growth-
promoting activity (70).
Systemic sclerosis is a connective tissue disorder characterized 
by fibrosis of the skin and caused by the activation of fibroblast 
and excessive deposition of the extracellular matrix, mainly 
type I collagen (71). Expression of EBI3, but not IL-35, was 
recently demonstrated to be decreased in the keratinocytes of the 
epidermis and Treg cells of the dermis in systemic sclerosis skin 
compared with normal skin, whereas injection of EBI3 alone into 
the skin improved mice skin fibrosis and addition of EBI3 alone 
in cultured dermal fibroblasts decreased type I collagen expres-
sion (18). Although the possibility that EBI3 may form a complex 
with endogenous p35 or other molecule cannot be excluded, EBI3 
itself may directly affect collagen expression.
CsEBI3, a fish EBI3 homolog, was recently identified from 
tongue sole (Cynoglossus semilaevis) and demonstrated immu-
nostimulatory properties depending on the conserved fibronectin 
type III domain as a self-standing cytokine (72). Bacterial infec-
tion of peripheral blood leukocytes enhanced CsEBI3 expression 
and caused extracellular secretion of CsEBI3, and purified 
recombinant CsEBI3 stimulated the respiratory burst activity of 
peripheral blood leukocytes and upregulated the expression of 
IL-1β, IL-8, myeloid differentiation primary response gene 88, 
IFN-induced gene 15, CD28, and chemokines (72). Thus, the 
EBI3 homolog alone may play a critical role in the antimicrobial 
host defense in fish.
p19
Self-standing activity of intracellular IL-23p19 was recently 
reported to play important roles as an endogenous activator 
of endothelial inflammation, promoting leukocyte adhesion 
to endothelial cells and transendothelial migration (19). 
Inflammatory mediators play important roles in the pathogenesis 
of vascular lesions that characterize different types of vasculitis, 
including giant-cell arteritis (73). It was recently demonstrated 
that p19 expression is enhanced by lipopolysaccharides or 
tumor necrosis factor-α in the absence of p40 in endothelial 
cells and that intracellular expression of p19 increases their 
cell surface expression of intracellular adhesion molecule-1 
and vascular cell adhesion molecule-1, which enhance the 
attachment of leukocytes and increase their transendothelial 
migration (19). Intriguingly, the intracellular expression of p19 
associated with cytokine receptor subunit gp130 and stimulated 
gp130-dependent activation of STAT3 signaling. In addition, 
endothelial p19 expression also associated with gp130 in the 
adventitial capillaries of inflamed temporal arteries of patients 
with giant-cell arteritis that do not contain p40 (19). However, 
how p19–gp130 interaction elicits STAT3 activation remains to 
be clarified.
CONCLuSiON AND FuTuRe 
PeRSPeCTiveS
Most of the cytokines identified to date have mainly pro-
inflammatory property, and there are only a few cytokines with 
anti-inflammatory properties, including IL-10, transforming 
growth factor-β, IL-27, and IL-35. Among them, IL-35 may be 
the only cytokine that possesses anti-inflammatory property 
alone. IL-10 is best known as an anti-inflammatory cytokine, 
but its immunosuppressive function is mainly limited to antigen-
presenting cells (74). For CD8+ T cells and B cells, IL-10 has 
pro-inflammatory functions and promotes proliferation and 
antibody production (74). This “double-edged sword” property 
significantly hinders clinical application of IL-10 because such 
pro-inflammatory functions might lead to adverse effects. So 
far, only the anti-inflammatory property is known for IL-35; 
therefore, this cytokine could be one of the most promising can-
didates for clinical application against allergic and autoimmune 
diseases. However, among the IL-6/IL-12 family cytokines, IL-35 
is considered to differ from the other cytokines (75). Although 
bacterially produced and purified recombinant proteins of EBI3 
and p35 were correctly folded and biologically active in com-
bination with p28 and p40, respectively, no biologically active 
IL-35 was reported to be formed when the p35 and EBI3 were 
combined (75). There are currently no reasons to explain this, 
but IL-35 might need additional, yet unidentified, molecules for 
efficient secretion and exertion of biological activity (75). One 
of the best criteria to prove the relationship between a bioac-
tive cytokine and its receptor should be to examine whether the 
recombinant cytokine can proliferate a factor-dependent cell line 
such as Ba/F3 cells expressing its receptor subunits. Ba/F3 is an 
IL-3-dependent mouse pro-B cell line used very commonly for 
assessing the potency of biologically active signaling molecules, 
including cytokines and kinases. In addition to IL-35, IL-Y, 
IL-39, and new cytokines to be identified in the near future need 
such studies to confirm the biological relationship.
Thus, the diversity in molecular structures and functions 
of the IL-6/IL-12 family cytokines is still expanding in vari-
ous physiological and pathological situations. Although the 
Human Genome Project was declared complete in 2003, and 
approximately 20,000 genes were identified, this number is 
much less than expected (76, 77). This gap is considered to 
be caused by the differences in subunit structure and alterna-
tive splicing. Growing diversity in the molecular structures 
and functions of the IL-6/IL-12 family cytokines should 
significantly contribute to filling the gap. Currently, the newest 
cytokine is IL-39, but some cytokine family members might 
be renamed because of new interleukins that might be found 
in the near future.
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